<div data-server-rendered="true" id="__nuxt"><div id="__layout"><div class="outer-container"><div class="content-container"> <div class="answer_container" style="min-height:calc(100vh - 54px);" data-v-0eba195e=""><div class="content_outer_container" data-v-0eba195e=""><div class="share_preview_container" data-v-0eba195e=""><div class="dialog_list" data-v-0eba195e=""><div class="dialog_item" data-v-0eba195e=""><div class="dialog_question fir_dialog_question" data-v-0eba195e=""><div class="question_con" data-v-0eba195e=""><h1 class="fir_question_content" data-v-0eba195e="">
                                    How did Enanta's operating expenses trend in Q1 2025?
                                </h1> <div class="user_slot" data-v-0eba195e=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/default_aime_user.ec532c9.png" alt="user" class="avatar" data-v-0eba195e=""> <span class="user_desction" data-v-0eba195e="">
                                        
                                        5/7/2025 05:29pm
                                    </span></div></div></div> <div class="seo-text-answer" data-v-0eba195e="">Enanta Pharmaceuticals reported a reduced net loss for Q1 2025 compared to the previous year, with a decreased operating expenses contributing to this improvement.</div> <div class="dialog_answer" data-v-0eba195e=""><div class="dialog_content" data-v-0eba195e=""><div class="answer_content" data-v-0eba195e=""></div></div></div></div></div> </div></div></div> </div> <div class="extra-module" data-v-261d488f=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/recommend-logo.4f9ccc8.png" alt="right-logo" fetchpriority="high" class="recommend-logo-img" data-v-261d488f=""> <div class="recommend-part" data-v-7790c618="" data-v-261d488f=""><div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/screener-recommend-icon.b007ca8.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime finds your next big stock</span></div> </div> <div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/stock-recommend-icon.77f1c78.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime powers your decisions</span></div> </div></div> </div> <div class="container-mask" style="display:none;"></div></div></div></div><script>window.__NUXT__=(function(a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,A,B,C,D,E,F,G,H,I,J,K,L,M,N,O,P,Q,R,S,T,U,V,W,X,Y,Z,_,$,aa,ab,ac,ad,ae,af,ag,ah,ai,aj,ak,al){return {layout:"default",data:[{noData:c,currentQuestion:d,textDescription:D,comeFrom:"AInvestShareLink",events:[],answerSource:i}],fetch:{},error:j,state:{sharePreviewModule:{loadJgySuccess:g,dialogRenderList:[{originAnswer:{input_media_info:[],session_round:1,agent_id:a,output_media_info:[],task_id:a,language:a,source:i,cache_builder:a,reply_action:"Answer",execute_mode:u,event_refresh_answer:a,param:"{\"entity_info\":{},\"add_info\":{\"ori_question\":\"How did Enanta's operating expenses trend in Q1 2025?\"},\"event_list\":[],\"client_ip\":\"\",\"question\":\"How did Enanta's operating expenses trend in Q1 2025?\",\"user_id\":\"dp98753566\",\"user_name\":\"\",\"trace_id\":\"abff52b1-19d9-4523-8f27-e258e3e40aeb\",\"session_id\":\"abff52b1-19d9-4523-8f27-e258e3e40aeb\",\"source\":\"ths_ainvest_lite_web\",\"input_type\":\"typewrite\"}",agent_info:[{info_type:"search",raw_data:{number:E,title:F,summary:G,full_summary:"Enanta Pharmaceuticals ( (ENTA) ) has released its Q1 earnings. Here is a breakdown of the information Enanta Pharmaceuticals presented to its investors. Maximize Your Portfolio with Data Driven Insights: Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions. Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio Enanta Pharmaceuticals, Inc., based in Watertown, Massachusetts, is a clinical-stage biotechnology company focused on developing small molecule drugs for virology and immunology indications. In its fiscal first quarter of 2025, Enanta Pharmaceuticals reported financial results highlighting a net loss reduction compared to the previous year, alongside significant progress in its development pipeline for treatments targeting respiratory syncytial virus (RSV) and type 2 immune diseases. Key financial metrics for the quarter included a total revenue of $17 million, primarily from royalties on sales of MAVYRET®, despite a slight decrease from the same period last year. Operating expenses decreased due to lower research and administrative costs, contributing to a reduced net loss of $22.3 million. Strategic highlights include the advancement of RSV treatments, with plans to report pivotal study results later in the year, and the expansion of the company’s immunology portfolio targeting chronic diseases. Looking ahead, Enanta Pharmaceuticals is poised to continue its strategic development efforts with a strong cash position forecasted to support operations into fiscal 2028. The company aims to leverage its innovative pipeline to establish a leading position in the treatment of RSV and immune-related conditions.",url:H,image_url:a,video_url:a,publish_time:I,search_extra_info:{search_burial_info:{id:v,uid:J,ab:{scene_id:K,layer_exp:[{layer_id:L,exp_id:M}]}}},simhash:"b67f2777bad596a8",msg_id:v}}],answer_chain_name:N,agent_mode:O,native_answer:a,come_from:a,text_answer:D,trace_id:e,cost:14268,event_names:a,question:d,fallback_type:P,input_type:Q,fall_back_reason:{fall_back_type:P,may_fall_back_reason:"UNKNOWN",risk_detail:{matched_words:[]}},session_id:e,first_return_cost:2182,cache_type:"no_cache",question_id:e,transfer_question:d,signal_type:"ON_COMPLETE",start_time:R,remote_svc:i,slots:[],answer_type:u,user_id:r,skill_name:w},renderList:[{type:"base_info",answer_path:"logs\u002FbaseInfo",logs:[],base_info:{trace_id:e,session_id:e,user_id:r,question:d,source:i,raw_question:d,version:"3.4.1",action_name:w,nlu:{entity:[{type:S,value:"ENTA.O",market:T}]},deep_research:c,deep_thinking:c,agent_mode:O},extra:{}},{answer_path:k,section:{id:l,info_texts:["Thinking"],show_type:m,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"begin"},logs:[],extra:{is_deep_research:c,deep_thinking:c}},{answer_path:k,section:{id:l,info_texts:["Querying Stock: ENTA Operating Expenses in Q1 2025"],show_type:m,choice:[],result_page:{},tag_info_list:[],is_last:b,status:U},logs:[],extra:{action:"Querying Stock",action_input:"ENTA Operating Expenses in Q1 2025",thought:"The user seeks to analyze Enanta's Q1 2025 operating expenses. I should focus on its operating expenses data for Q1 2025. I will use FinQuery for the data mentioned above."}},{answer_path:f,section:{id:x,info_texts:[],show_type:s,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:k,section:{id:l,info_texts:["Searching Web: Enanta's Q1 2025 Operating Expenses"],show_type:m,choice:[],result_page:{},tag_info_list:[],is_last:b,status:U},logs:[],extra:{action:"Searching Web",action_input:"Enanta's Q1 2025 Operating Expenses",thought:"I am unable to obtain Enanta's Q1 2025 operating expenses using FinQuery, now I will try again using Search."}},{answer_path:f,section:{id:x,info_texts:[],show_type:s,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:f,section:{id:x,info_texts:[],show_type:s,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:k,section:{id:l,info_texts:["Generating Answer"],show_type:m,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"ongoing"},logs:[],extra:{}},{answer_path:f,section:{id:y,info_texts:[],show_type:z,voice_txt:"En",text_answer:V,rich_text:V,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:f,section:{id:2000,info_texts:[],show_type:z,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[{url:H,image_url:a,video_url:a,title:F,summary:G,index:E,publish_time:I,search_id:v,search_uid:J,search_ab:{scene_id:K,layer_exp:[{layer_id:L,exp_id:M}]},jump_type:"normal"}],is_last:b},logs:[],extra:{}},{answer_path:f,section:{id:y,info_texts:[],show_type:z,voice_txt:A,text_answer:A,rich_text:A,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"extraInfo\u002FsourceLink",logs:[],extra:{span_id:a,link_id:a,source:a,link_text:a,link_param:a,link_ids:[]}},{answer_path:f,section:{id:1001,info_texts:[],show_type:"fenshi",choice:[],result_page:{},tag_info_list:[{stock_info:{code:"ENTA",market_id:T,name:W,domain:S},pos:g,section_id:y,txt:W,jump_type:"pos_fenshi"}],is_last:b},logs:[],extra:{}},{answer_path:k,section:{id:l,info_texts:["Completed"],show_type:m,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"end"},logs:[],extra:{}},{answer_path:"suggest\u002Fquestions",section:{id:10002,info_texts:[],show_type:"result_page",choice:[{display_text:n,query_text:n,trace_info:{item_id:"a8adb144fbee0fe7eb1d5a2c1e53ba8d",item_type:h,item_name:n,rec_info:X}},{display_text:o,query_text:o,trace_info:{item_id:"59a5a61f08dbc809f12790ea3c849734",item_type:h,item_name:o,rec_info:Y}},{display_text:p,query_text:p,trace_info:{item_id:"528789aa3777d4c512462a9876e6f0c9",item_type:h,item_name:p,rec_info:Z}}],result_page:{components:[{show_type:"lowcode",title_config:{show_type:"title1",data:{h1:a,h2:a},config:{display:c,txt_style:g,type:"1",display2:c,url:a}},request_config:[{source_type:_,related_name:$}],puuid:B,tag:a,category:"custom",uuid:aa}],global:{urp_static_data:[{name:$,value:{status_code:g,columns:[{type:q,index_name:ab,key:ab},{type:q,index_name:ac,key:ac},{type:q,index_name:ad,key:ad},{type:q,index_name:ae,key:ae},{type:q,index_name:af,key:af}],datas:[{send_text:n,item_type:h,rec_info:X,display_text:n,rec_reason:a},{send_text:o,item_type:h,rec_info:Y,display_text:o,rec_reason:a},{send_text:p,item_type:h,rec_info:Z,display_text:p,rec_reason:a}],dataSize:_,status_msg:a}}],lowcode_type:"shunda",interface_request_list:[],lowcode_json:{stack:c,visible:b,childLimit:9999,label:ag,type:"thslc\u002Fthslc-common-container",leaf:c,animate:[],version:"1.0.1",script:[],props:[],path:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fkernel-thslc-resource\u002Fresource\u002Fainvest\u002F0Ae514cfA4\u002Fjs\u002F_thslc-common-container_1.0.1_index.js",isTransparent:b,style:{"background-color":a,"box-shadow":"0px 0px 0px",color:a,width:t,"min-height":"100%",position:ah,height:t},isMaterial:c,id:ag,needTheme:c,hasEditor:c,packed:c,events:[],child:[{readmeUrl:"https:",stack:c,visible:b,customStyle:a,childLimit:g,label:"路径推荐",type:"iwencai\u002FrecommendList",leaf:b,version:"1.12.0",animate:[],url:C,componentUuid:aa,script:[{name:ai,id:20240320,content:"return {\r\n  created: function created() {\r\n    this.isActive = !Boolean(this.$parent.$parent.$parent.$parent.$parent.$parent.question);\r\n    var showId ='tkPanel_bottomTag';\r\n  this.buryPointId = showId;\r\n  }\r\n};"}],props:{recommendList:[],isTransparent:b,renderType:"blue"},path:C,meta:{custom_editor_url:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0editor.js",js_url:C},style:{"background-color":a,margin:"-12px 0px -12px 0px",color:a,display:"block",width:t,position:ah,height:t},isMaterial:b,_id:19,id:ai,hasEditor:b,packed:c,events:[],isSetDefaultValue:b}]}},page:{layout:{layout_data:"[{\"uuid\":\"ztxxx06c0a024223920bbbeb1e0926\",\"showType\":\"lowcode\",\"children\":[]}]"},render_for:aj,voice_txt:a,tracking_info:{},uuid:B},order:{is_auto:c,render_for:aj,chart_type:"command",puuid:B}},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"suggest\u002Finputs",section:{id:10000,info_texts:[],show_type:"choice",choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"logs\u002Ftrace_debug",section:{id:1005,info_texts:[],show_type:s,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{action_name:w,with_paid_index:c,no_refresh_answer:c,answer_source:{agent_id:a,agent_name:a,execute_mode:u,answer_chain_name:N},is_deep_research:c,deep_thinking:c,create_time:1746610180280},is_last:b}],questionItem:{data:{qStr:d,encodeFlag:c,imageData:j,docsData:[],quoteData:j},tplType:"question"},events:ak,agentId:a,param:{entity_info:{},add_info:{ori_question:d},event_list:ak,client_ip:a,question:d,user_id:r,user_name:a,trace_id:e,session_id:e,source:i,input_type:Q}}],userId:r,userName:a,startTime:R,mobileType:a,comeFrom:a,textConstants:{},dialogContainer:j,endSignal:c,theme:"white",showTracePopup:c,traceListData:[],chatTraceTargetIndex:g,traceTableData:j,showMask:c}},serverRendered:b,routePath:"\u002Faime\u002Fshare\u002Fhow-did-enantas-operating-expenses-trend-in-q1-2025-6d4c28\u002F",config:{_app:{basePath:al,assetsPath:al,cdnURL:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fiwc-aime-seo\u002F"}}}}("",true,false,"How did Enanta's operating expenses trend in Q1 2025?","abff52b1-19d9-4523-8f27-e258e3e40aeb","other\u002FopenAnswer",0,"llm_generated","ths_ainvest_lite_web",null,"progress\u002Fsearching_for",1000,"searching_for","🔎 What were Enanta's total operating expenses in Q1 2025?","🌟 What was the breakdown of Enanta's operating expenses in Q1 2025?","💼 Did Enanta's operating expenses increase or decrease in Q1 2025?","STR","dp98753566","signal","auto","agent","d6b1483862704cda_0","review stocks",999,2001,"rich_text",".","39196","\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0index.js","Enanta Pharmaceuticals reported a reduced net loss for Q1 2025 compared to the previous year, with a decreased operating expenses contributing to this improvement.",6,"Enanta Pharmaceuticals Advances in Virology and Immunology","Enanta Pharmaceuticals ( (ENTA) ) has released its Q1 earnings. Here is a breakdown of the information Enanta Pharmaceuticals presented to its investors. Maximize Your Portfolio with Data Driven Insights: Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top perform...","https:\u002F\u002Fwww.tipranks.com\u002Fnews\u002Fcompany-announcements\u002Fenanta-pharmaceuticals-advances-in-virology-and-immunology","2025-02-12","d6b1483862704cda","oeqxkhszf","oeqxkhszf_layer","base","agent_common_v2\nagent-summary","normal_agent","NONE","typewrite",1746610166012,"stock","185","thinking","Enanta Pharmaceuticals reported a reduced net loss for Q1 2025 compared to the previous year, with a decreased operating expenses contributing to this improvement[^6]","Enanta","2+679_496_21_554+0+0+abff52b1-19d9-4523-8f27-e258e3e40aeb+a8adb144fbee0fe7eb1d5a2c1e53ba8d+llm_generated+aimeTagAnalysis+0+0.08706369251012802+1","2+679_496_21_554+0+0+abff52b1-19d9-4523-8f27-e258e3e40aeb+59a5a61f08dbc809f12790ea3c849734+llm_generated+aimeTagAnalysis+0+0.0776892900466919+2","2+679_496_21_554+0+0+abff52b1-19d9-4523-8f27-e258e3e40aeb+528789aa3777d4c512462a9876e6f0c9+llm_generated+aimeTagAnalysis+0+0.032788749784231186+3",3,"recommend_query_list","ztxxx06c0a024223920bbbeb1e0926","send_text","item_type","rec_info","display_text","rec_reason","root","relative","iwencai\u002FrecommendList0326","aigc",Array(0),"\u002F"));</script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/b929a16.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/28ccbec.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/d9802b5.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/2077034.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/1e0f8d6.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/7a5f495.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/921844b.js" defer=""></script>